Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-3797
- Development stage
- Phase 1
- Lead developer
- Suncadia Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
HRS-3797 is a novel chemical drug classified as a Class 1 new drug in China. It is being developed as an injectable formulation and has received clinical trial approval from the National Medical Products Administration (NMPA) for tracheal indications. The drug is currently in Phase 1 clinical development, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in Chinese subjects. The precise mechanism of action and molecular target have not been publicly disclosed. Initial development was by Fujian Suncadia Pharmaceuticals; current development appears to be associated with Jiangsu Hengrui Pharmaceuticals.
Beyond the preview
Go deeper on HRS-3797.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-3797.